

A BRAND NEW ERA FOR MADE IN TAIWAN

VOL eMags

Discover Asia's treasure island - Taiwan. Find out about the leading companies of Taiwan's business landscape from biotech to ICT.

Scan the QR Code to access the eMag



FOLLOW US:

Twitter & Instagram
@voicesofleaders
linkedin.com
/voicesofleaders

This special report was produced by **Voices of Leaders** in collaboration with **Fortune Magazine**.

Editorial Director:
Javier Madero.
Written by: Daiva Sen.

Where do you look for a country whose global reputation has improved in the wake of 2020's pandemic? Rather than efficiency — delay, denial and confusion are the recurring COVID-19 response themes. Worldwide, federal and local governments have clashed, caught in a no-man's land between protecting public health or ever-shrinking economies, whilst everyday life has been rendered unrecognizable. So, in answer to that opening question, whilst it's slim-pickings — look no further than a little island off the coast of mainland China and you have the clearest answer.

During the past few months, life in Taiwan has been like living in a bubble, which is to say, due to masterful control of the pandemic, it has remained largely unchanged. President Tsai Ing-Wen's government has been globally lauded for its effectiveness, taking measures such as temporarily banning exports of PPE to ensure domestic supply, later exporting (even donating) face masks, and investing heavily in manufacturing companies — enabling them to elevate their production to previously unimaginable numbers.

At this moment of crisis, when economic opportunities have been few and far between, the Made In Taiwan brand has found itself back on the global map, stepping out of the shadow of its giant neighbor — China. With the arrival of COVID-19, it is not only the trade war or rising labor costs in China that is giving Taiwanese manufacturing the edge. The countries' vastly differing narratives during the pandemic mark a telling contrast — the Chinese one being a story of unreliability with faulty testing kits and PPE being sent to Europe, while Taiwan has excelled in the production of PPE and relevant medical products, doubling, even tripling production in some cases. It is as simple as Michael Chang, Chairman & CEO of PPE manufacturers CSD says — “because of COVID-19, the manufacturing for PPE in Taiwan has been noticed worldwide.”

Taiwan's manufacturing aptitude should not come as too great of a surprise. Prior to the pandemic, Taiwan already boasted examples of manufacturing companies achieving numbers against the odds. An example is aircraft equipment manufacturers, Chaheng Precision, whose Chairman, Jane Chi, explains that the company established themselves as a fan blade manufacturer within 18 months, as opposed to the 40 years which they had been told was the norm. Nonetheless, such success stories have not been as globally relevant to draw an international gaze as we are now seeing with PPE.

Sophia Chiu, Chairman of TECO, identifies a slightly different problem, that once upon a time “MIT (Made In Taiwan) was often considered as MIC (Made In China), people could not tell the difference between Taiwan and China.” Now, there is a notion that things are changing, with the difference being clearly marked by quality, as during the pandemic Taiwan proved their efficiency while in China's case serious question marks were raised, largely around the reliability of their products.

Dr. Sy-Ming Guu, President of Mytrex Health Technologies, who participated in face mask production goes on to explain that moreover, Taiwan, rather than taking advantage of the vulnerable at this moment of crisis, put their quality PPE products at affordable prices — a mindset fostered by government regulation of the domestic market.

Taking into account the cross-sector collaboration that marked the ‘Team Taiwan’ COVID-19 response, Howard Lu of Evermore Applied Materials identifies the wider reaching implications this may have for Taiwan's business community, as “the manufacturing sector could also leverage such an image.”

As a precursor to its newly-growing sectors, there are areas where Taiwan has excelled over the last half-century, such as ICT and electronics. With the likes of TSMC and WIN Semiconductors, its semiconductor sector similarly is one of the most potent in the world. Nonetheless, despite the established and enduring success of these industries, as Daphne Hsieh, co-founder of REXLite acknowledges the difficulty of creating a brand in Taiwan and that “making a brand is not a common thing to do.” This could be set to change as a marriage of 4IR technologies and burgeoning biotech/medical device sectors starts opening up new possibilities. Dr. D.J. Hsieh, ACRO Biomedical CEO explains — “once you combine the IT industry, 5G, and all these telecommunications together with the biotech industry, it is going to open up a new field.” Dr. Ae-June Wang, President of Andros Pharmaceuticals agrees, saying that “Taiwan holds an excellent position in the current scenario which has accelerated digital transformation and built a new integrated business model, including the application of AI, IoT, data analysis, blockchain and smart platforms. All of these great potentials will move up the value chain of the Made in Taiwan brand in the global market.” With the integration of 4IR therefore, all sectors are going to undergo a level of transformation, meaning a brand new age for MIT may be right around the corner.

TAIWAN'S BIOTECH AND MEDICAL DEVICES RENAISSANCE

As the established Taiwanese ICT industry looks to get involved in its growing biotech and medical devices industries, Taiwanese brands may well become a more common occurrence.

Over the past decade, Taiwanese biotech's collaboration with the government, improvement of R&D, and integration of cutting-edge technology — has brought it to the precipice of making a global impact. Quark Biosciences Chairman & CEO, Dr. Johnsee Lee maps out this progress — “in terms of the listed biotech companies, we have grown more than three times in the last ten years and the market cap has grown about ten times.”

Having witnessed this growth, Sybil Yang, Phalanx Biotech Chairman & CEO, states her confidence that Taiwan's biotech industry “is poised for taking off” and “can follow the same pattern and spirits as the ICT industry.” Yang is not the only one to compare Taiwanese biotech to more established sectors, as Dr. C.Y. Huang, Chairman of NatureWise Biotech & Medicals, shares this optimism, putting forward that “Taiwan's biotech industry will also enjoy the same kind of reputation as Taiwan's electronics industry”. It is high and promising praise indeed if those within the biotech sector see these comparisons as realistic trajectories.

Optimism in the future of the biotech sector is supported by the ambition, and self-confidence of leaders within it. “We believe this kind of technology will change the world” says LumiSTAR Biotechnology CEO, Dr. Yu-Fen Chang, of their design and detection light technology, which has been mobilized in the fight against COVID-19. Elsewhere, Cold Spring Biotechnology President Pasteur K. Tai states “Our company, if we want to do anything, we always think we want to become the number one.” International expansion is another motif, as Wendy Lu, Managing Director of Wendy International plans to make her business a “global enterprise.”

Dr. Lee-Cheng Liu, EirGenix President & CEO, is similarly internationally minded. He explains that given their high revenue compared to most biotech companies, having already achieved IPO public listing at home, they have their eyes on the bigger prizes of NASDAQ and NYSE. PharmaEssentia is in the same boat, their CEO Dr. Ko-Chung Lin revealing “JP Morgan and UBS have talked to us to see if we can get listed in NASDAQ. We have spoken with the likes of JP Morgan, Morgan Stanley, and try to see if we can get listed in Hong Kong.”

These common denominators of ambition and confidence are a necessary foundation, but there is more to backup these claims than simple fighting talk.

FINDING A NICHE

Despite excelling in electronics and ICT, apart from the likes of ASUS and Acer, there has not been a lot of room for Taiwanese brands to establish their own names globally. Manufacturing services for bigger international companies has tended to be the safer bet. Will Lu, Zylux Acoustic CEO explains that it is flattering when brands like Google choose to work with Taiwanese companies such as them, so Taiwan has long played to this strength.

Taking this into account, in establishing their own brands, it is sometimes hard for Taiwan to avoid being eclipsed by giants, much as the case with China and manufacture pre-pandemic. Now, a new desire to establish Taiwanese brands is coming to the fore. Take Mark Yang CEO of GaleMed for example, who cites becoming a global “OBM player” as the company's primary long-term goal. Ken Liu, Chairman of Advanced Green Biotechnology meanwhile, identifies the international market's increasing prominence as their exports are growing every year.

Biotech and medical devices offer the opportunity of a simple formula — identify a specialty, excel, and expand. Paul Chuang, Chairman of medical devices company AVITA explains his sector's lay of the land, highlighting that in comparison to IT, the range of products available in medical devices is far more varied, which forms an ecosystem perfect for Taiwan's small domestic market and largely SME-formed landscape. Pharmaceutical company CCPG are an example of a company acting on the potential offered by medical devices' variety, Chairman Derek Wang explaining that they are working on “special formulations that act in concert with special medical devices, such as pre-filled syringes, pen injectors, small mist inhalers...”

Within medical devices therefore, finding a niche is the order of the day. This same logic can be applied to biotechnology. With sectors such as stem cell technology, antibodies, precision medicine, regenerative medicine — all with their respective sub-sectors, there is more than enough room for biotech SMEs to grow, and regarding that growth

— the sky is the limit if you can corner just one of the many markets available. Dr. William Hung, CEO of Maria Von Med-Biotechnology explains that on top of their skincare products they “help other people with their products, and what we call stem cells or regenerative medicine”, demonstrating the numerous opportunities that exist for flexible and specialized companies.

The seemingly infinite options in these fields being taken advantage of, is forming an increase in both the sheer number of companies, and also their diversity. Without giants monopolizing narrow markets like in IT, there is plenty of room and promise for those able to make a niche market their own. As PuriBlood CEO, Luke Chen says “Taiwan's small market is suitable for niche markets in individual fields, creating a global competitiveness for the biomedical industry.”

It is true enough that PPE manufacturing may no longer be considered particularly ‘niche’ given the current global situation. Nevertheless, the huge rise in demand brought about by the pandemic, means that multiple companies are not only a possibility, but a necessity. Other non-PPE companies have also made important contributions to COVID-19 treatment, like GaleMed, whose background in respiratory care has been channeled towards making consumables for ventilators.

Taiwan has also joined the global search for vaccines and rapid testing kits. Both Medigen (in collaboration with the NIH in the U.S.) and Adimmune are developing COVID-19 vaccines. Cold Spring Biotech meanwhile, are contributing several quick screening solutions including a portable PCR device, a IPMx and nucleic acid test, and a rapid test.

GREAT OAKS AND LITTLE ACORNS

“Great oaks from little acorns grow speaks volumes about companies in Taiwan” says Andros Pharmaceuticals' Dr. Ae-June Wang. Having successfully negotiated the crucial first steps of finding their identity, sustaining momentum is the next challenge for many of Taiwan's biotech companies. Much of this momentum may come with experience. As ACRO Biomedical's Dr. Hsieh says, “I think currently there is a gold rush, everyone seems to be very excited about the opportunity for the biomedical field. Right now, there are more young entrepreneurs in this industry than older,



experienced ones, so I think it is a learning process for the younger ones.” Naturally, this process will take time.

As Dr. Hsieh encourages young biotech entrepreneurs to hone their art, a different kind of patience is encouraged by Phalanx Biotech's Sybil Yang — “the talents leading the biotech companies in Taiwan are mostly technology-oriented with products at the protocol stage. However, once they commercialize their products, expand globally and learn how to integrate cross-border talents, I would not be surprised if Taiwan's biotech becomes the next generation of leading industry, like the ICT did.” Yang's comment both echoes those of other biotech leaders who predict biotech and medical devices will be Taiwan's next giant industries, and suggests this huge success may be accelerated by a possible wave of regulatory approvals.

WAITING FOR THE BOOM

TECO's Sophia Chiu says when it comes to business “reliability is more important than anything else.” Perhaps now, more than ever, when the need for materials has been so imperative, this prioritization seems more pertinent than ever — a wake up call to many. The old adage of “you get what you pay for” may come to people's minds, as quality and reliability come to conquer a penny pinching, labor cost-driven mindset in the future of manufacturing. Taiwan would definitely be a beneficiary of such a reshuffle of priorities.

The involvement of Taiwan's established electronics, ICT, and semiconductor sectors may well be the boost its emerging industries need, both in terms of investment, but more importantly, in accelerating the digitalization processes which will convert them into some of the leading companies of the future in their respective sectors. The opportunity offered by the involvement of other industries is highlighted by Superintendent of Cheng Hsin General Hospital Dr. Jeng Wei who summarizes “Taiwanese industries realized that it is time to cooperate with the medical science field and they are eyeing this field because the conventional IT industry is a bit saturated at this point, so it is our chance to create a new brand for medical innovation and biotechnology.”

A boost from Taiwan's biggest companies is exactly the kind of animation the medical devices and biotech sectors need, as with their fuse well and truly lit, it is just a matter of accelerating and waiting for the imminent boom.

VOICES OF TAIWANESE LEADERS

Beyond biotech and medical devices, Taiwanese business leaders' visions demonstrate a diverse range of voices across its established and emerging sectors. Demonstrating both openness and willingness to change, new leadership and changing attitudes are breathing different kinds of life into the wider business community of Taiwan.

One of these winds of change, is a generational transition. Many Taiwanese companies continue to be privately-owned and these are gradually being handed over to the next generation. Taiwan's millennial/gen-z leaders make up for what they lack in experience with fresh eyes, which look upon Taiwan's business landscape from a more international perspective. Indeed, many of these new leaders have studied abroad, most commonly in the United States. With these international view-points, come different ambitions and values, which whilst not overriding the traditions in Taiwan, color them with a different tint.

Yi-Chiu Group is a perfect example of this. Jonathan Chin is preparing to take the reins from his father Chia-Hung Chin, Yi-Chiu Group founder and Chairman. Jonathan is already pushing for a move away from mineral oil and towards renewable energy and other emerging industries. In place of resistance to the new generation, there seems to be a mutual respect and acknowledgement of a need for change. The mother-son team at Maria Von is another example of this — Dr. May-Yue Huang, Chairman and founder calls her son Dr. William Hung (CEO) her “teacher”, with both admitting to a learning experience working together, which flows both ways.

The changing of the guard in terms of leadership, is not only a question of age, but attitude. GaleMed bringing in CEO Mark Yang, and CDIB with a new management team led by Chairman Angelo J.Y. Koo are examples of a new prioritization of corporate culture. Combined with this idea of a more corporate image, is the aforementioned principle of sustainability which is becoming increasingly prominent in Taiwanese businesses. Welch Lin, President of Taishin Financial Holdings, highlights the company's increasing commitment to Social Corporate Responsibility, cooperation with the Taiwanese government over the 17 UN SDGs being a new focus.

On top of this, an urgency for adaptation to new technologies permeates through C-suite leadership and private ownership. Speaking of new technologies in the ICT sector, specifically AI, Planet Technology's Chairman & CEO Jack Chen says “If people avoid it, they will be phased out from the market.” This warning echoes throughout both established and up and coming Taiwanese industries, and can be applied to general use of 4IR technologies, beyond AI.

The centrality of technology to development is underlined by the emergence of technology-centered businesses in different fields. Within consultancy for example, is LeadBest, whose CEO, Neil Lee describes “technology-driven business development” as the company's main focus, and in medical devices — Biomedcare, who provide AI-driven medical solutions.

It is clear that Taiwan's innovators and business leaders have their eyes fixed upon a more ambitious future. The crux of this future being attitude — openness towards new technology, vision for international markets and desire to build on MIT's momentum — forming a new era not just for MIT, but for Taiwanese brands as a whole. ●

FROM TEMPERATURE TO STRESS: AVITA MEASURES UP.

Business is booming for Taiwan's leading thermometer manufacturers.



Rising to the challenge of an unprecedented surge in demand, medical products company AViTA has ramped up production, thermometers being key to the monitoring of COVID-19 symptoms. Coupled with record revenues in July and June, by the end of the year AViTA expects to have more than tripled their production since December 2019.

Although they are the biggest thermometer manufacturer in Taiwan and the demand for their leading product is higher than ever, resting on their laurels and sheltering under this security is not on the AViTA agenda. This year they will launch the Psychological Stress Indicator (PSI), a first of its kind blood pressure indicator which can help you measure your stress levels, for home and personal use. AViTA President, Frank Jih explains that Taiwan's leading hospital verified the test as “over 85% accurate compared to the questionnaire that the doctors use when the patients come to them.”

To ensure the continued production of innovative products, R&D and the integration of new technologies is crucial for AViTA. Indeed, for Chairman Paul Chuang, this is the crux of the Taiwanese manufacturing industry's future. He predicts that “because of 5G, IoT, AI, our industrial leaders and manufacturers will start to grow and to be seen by the world.” AViTA themselves have already deployed a Bluetooth thermometer in the U.S which uploads information to servers in real-time — a perfect example of a successful IoT technology application.

Simultaneously tripling production and implementing cutting-edge technologies, AViTA is proof of the medical products industry and the Made In Taiwan brand's potential for exponential growth in the coming years. ●



EIRGENIX – READY TO LEAD THE WAY IN PHARMACEUTICALS

Through its commitment to innovation and providing high-quality and cost-effective biopharmaceutical products and services, EirGenix strives to become a prominent player in the global pharmaceutical market.

In 2018, the global market for pharmaceuticals reached a value of US\$1.2 trillion, up over US\$100 million from the previous year. According to the IQVIA Institute for Human Data Science, rapid growth will continue to push the market to US\$1.5 trillion by 2023. The current digital revolution has generated a fiercely competitive market demanding innovation and efficiency from pharmaceutical companies. Fortunately for Taiwan-based EirGenix, its achievements over the past six years since its launch in 2012 are proof that it is ready to thrive in the market for years to come.

With a vision to provide affordable drugs and healthcare for all, EirGenix established two business units – one operating as a contract development and manufacturing organization (CDMO) providing clients with biopharmaceutical services to develop their products, and a product development unit creating a portfolio of biosimilars, biobetters, and novel biologics. EirGenix has received recognition for its achievements in both units.

In January 2019, EirGenix initiated operations in its new commercial mass production facility in Zhubei, Taiwan. The state-of-the-art facility is furnished with the latest biomanufacturing technologies and equipment and is designed to produce at least 1 kg of monoclonal antibody at its maximum capacity – a significant stepping stone for EirGenix to break into the global market. In April 2019, EirGenix announced its global licensing agreement with Sandoz AG, a Novartis division and a global leader in generic and biosimilar drug manufacturing. The agreement is a first for Taiwan's biopharmaceutical industry and has been the most significant milestone for EirGenix's product development unit so far. "This collaboration with Sandoz makes us a global pharmaceutical manufacturing company," states EirGenix CEO, Dr. Lee-Cheng Liu.

In June 2019, EirGenix completed the final stage of its initial public offering on the Taipei Exchange, placing it in a stronger financial position. EirGenix received its first audit from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in September 2019, the company's first inspection from a foreign regulatory authority. The initial feedback has been positive and official approval is expected before the year's end. The approval from Japan's PMDA will set the precedent for EirGenix's further pursuit of international compliance to become a global market player. With its strong vision, EirGenix is poised to fortify its position as a key player in the global pharmaceutical market. ●



Dr. Johnsee Lee
Chairman & CEO of
Quark Biosciences,
Founder & CEO of
Personal Genomics

Quark Biosciences – Innovative Solutions for Precision Healthcare

Established in 2012, Quark Biosciences (QuarkBio) was founded on the premise that the one-size-fits-all medical approach has become obsolete and that the emerging requirements of precision healthcare solutions need to be met in an efficient and affordable manner for patients.

By partnering with doctors and researchers worldwide, QuarkBio focuses on providing innovative molecular diagnostics for cancers and fertility treatments. These diagnostics assays are developed using a patented chip-based multi-gene analyzer, PanelChip. A 100-gene cancer assay can be completed in two hours by PanelChip with very high accuracy, minimum hands-on time and affordable costs.

QuarkBio has also devoted a significant effort in developing microRNA for liquid biopsy. Being responsible for 90% of human gene expression regulations, microRNA is becoming one of the most important biomarkers for precision medicine applications. Moreover, at present, QuarkBio owns one of the most extensive databases for microRNA.

"We are discussing collaborations with a number of global partners because technology is only a part of the game; a lot of other expertise and resources will be needed to grow into bigger markets," says Dr. Johnsee Lee, Chairman & CEO of QuarkBio. Such collaborations will be fundamental to resolving further unmet clinical needs.

Under the umbrella of QuarkBio comes Personal Genomics, a company which aims to make personalized genomics a reality through its opto-electronic single molecule sequencing. "The technology combines Taiwan's semiconductors, electronics, life science and biochemistry to produce a revolutionary sequencing technology," says Dr. Lee, and it is clear that, thanks to its cutting-edge technology and a commitment to innovation through collaboration, both QuarkBio and Personal Genomics have a bright future ahead. ●



PHARMAESSENTIA – LEADING TAIWANESE BIOTECH COMPANY ENTERS ROBUST GROWTH PHASE WITH FURTHER EXPANSION IN THE U.S.

Polycythemia vera (PV) is a rare blood disease that causes the bone marrow to produce too many red blood cells, making the blood thicker than normal. Untreated PV can lead to life-threatening complications, but thanks to early diagnosis and advancements in the development of drugs to treat blood diseases, PV can be treated and significantly improve patients' quality of life.

PharmaEssentia is a leading Taiwanese biotech company spearheading the development of drugs that combat myeloproliferative neoplasms (MPNs) – also known as bone marrow disorders – such as PV, essential thrombocythemia (ET), and myelofibrosis (MF). In the United States, PharmaEssentia has established an office in Burlington, Massachusetts. The company's drug BESREMI®, developed jointly with AOP Orphan Pharmaceuticals, was given the green light in the European Union in 2019 and is set to be approved in the U.S. in early 2021, which will certainly bolster its presence in the American market.

"Our goal is to treat the disease as early as possible in order to prevent the disease progression," says PharmaEssentia CEO Dr. Ko-Chung Lin. "We want BESREMI® to be available for patients in the U.S. because PV is a really devastating disease."

PharmaEssentia's flagship drug is set to be the first product approved for the frontline treatment of PV, a major step forward to having approved therapy for the initial treatment of the disease.

U.S. EXPANSION

Currently, PharmaEssentia is entering a phase of tremendous growth and opportunity, steadily moving from being a research and development company into a fully commercial organization with an operational sales force. This would pave the way for a steady revenue stream enabling PharmaEssentia to invest in other research activities and open it up for future expansion. Being situated by the Boston area provides them critical opportunities to collaborate with the business community and academia, as well as access talent both within and outside of the Boston area.

PharmaEssentia is looking to go ADR and be listed in the NASDAQ in the coming years. With such robust expansion and a firm commitment to combating devastating diseases, PharmaEssentia is not only saving lives, but ensuring patients' higher quality of life. ●



CCPG — A MATCH MADE FOR BIG PHARMA COLLABORATIONS

Taiwan-based CCPG and its subsidiaries have been specializing in generics manufacturing for nearly 70 years, and are still eager for further expansions and collaborations.

China Chemical & Pharmaceutical Group (CCPG) celebrates its 70th anniversary in 2022. The company can look back on this long history with pride, having established themselves as a specialist in generic products, with over a hundred BA/BE products to their name. Its mother company, CCPC, has held collaborations with leading US pharmaceutical companies for a couple of years and is exporting to the United States. Through the many branches of its speciality, nearly 70 years on, the group is still widening its horizons.

A current star of the group is biotech and synthetics subsidiary and API experts CCSB, who are behind over 30 products including immunosuppressant, oncology, and peptides. CCSB has been collaborating with both US and European generic and branded drug companies for a number of years, and together with their US sales office, Pharmaports LLC, has formed an international network providing pharmaceutical ingredients and finished dosages.

The group's fastest-growing market involves a near neighbor. Their latest joint venture is a

fully-fledged collaborative effort, as they provide a newly-constructed manufacturing site for their Japanese partners' technology and equipment, with the products being exported to both Japan and China. Expanding new markets this far into their career, shows that the spark of ambition has certainly not been extinguished.

New markets are not the only exploration on the agenda. Chairman Derek Wang explains that the group is "getting involved in different categories of generics" as they invest in new technologies. Whilst emphasizing that their specialty and priority is still generics, diversification is something that the company is looking into, as they explore new products which still fall within their R&D capacity and know-how. Medical devices is another area in which the group may find itself becoming increasingly involved with pre-filled syringes, small mist inhalers and pen injectors being highlighted as items in their pipeline with the possibility of launching in the near future.

CCPG's flexibility allows them to "refine" past successes. Mr. Wang explains that through

improving on successfully launched products, the group is laying the foundations for the next generation of generic products. Indeed, if there were any company up to this task, one with this level of experience is clearly the perfect candidate.

Undertaking new challenges — whether they be new markets, new products, new manufacturing sites or new partners — CCPG and its affiliate companies have spent the last seven decades forming a large network of international companies and a deep well of expertise in generics. Drawing on both, CCPG hopes to continue working with their affiliate companies on vertical integration, investing in new technologies and opening collaborations with the world's largest pharmaceutical companies, some of which have already begun. Following this current trajectory, CCPG may well be celebrating its 70th anniversary with some of its most high-profile projects to date. ●



MADE BY GALEMED

Welcome to GaleMed 2.0. A company with over 33 years of experience in the respiratory and anesthesia care marketplace, has had a record-breaking 2020.


GaleMed has been very much involved in the global fight against COVID-19, creating consumables for ventilators, their speciality being respiratory care. At every stage of a COVID-19 patient's journey, GaleMed can play a key role, applying their decades of experience in the area.

Having recently been acquired by Nexus Point Capital, the family business changed hands, with new CEO Mark Yang at the helm. Mr. Yang's number one priority since his arrival in June 2019 has been a change of corporate culture which sees investors take a more central role, whilst the customer and patient remain the number one priorities. His arrival has also seen a reshuffle of the management team that has proved essential to negotiating a year of unprecedented activity.

Following a year of record revenue, Mr. Yang reemphasizes the company's priorities and greater responsibilities — "On one side we're happy with our financial performance, on the other side we try to do our best to help with the medical manufacture or even the medical society and help

with the impacted population — that's our goal."

This far into GaleMed's life it has experienced its most successful year yet in terms of revenue, largely due to its products' role in the treatment of COVID-19. Using this as a lift off point, there



is a double-pronged approach that bodes well for GaleMed's future — their OEM site in Xiamen, China, collaborating with global medical devices companies whilst their OBM is focused in their Taiwanese site. In the coming years, GaleMed plans to place more emphasis on the latter element, and expand its own international brand within respiratory care.



In the future, GaleMed is also looking to channel more attention and funding to R&D, as they develop their own products for OBM business. GaleMed is conscious, especially given the current context, that quality is imperative when it comes to medical devices, which is why now and going forward, it is at the forefront of its mind and the core of its new corporate culture. Mr. Yang summarizes GaleMed's quality assurance saying "whether you're born Made In China, or born Made In Taiwan, as a corporation in particular, working with GaleMed 2.0 in particular, we have to emphasize and prove to our customer, any finished products, whether it is Made In Taiwan or Made In China, the quality is the same. Made by GaleMed is the most important thing." ●



MARIA VON — TACKLING SKIN-DISEASE WITH REGENERATIVE STEM CELL

With a background in clinical skincare, Maria Von Med-Biotechnology has leveraged their years of experience, and channeled it into cutting-edge regenerative stem cell technology.



Dr. Mei-Yue Huang,
Chairman



Dr. William Hung,
CEO

The dermatological roots of biotech skincare specialists Maria Von, are evident in both the background of their founder, and their current attitude. Dr. Mei-Yue Huang founded the company 35 years ago, bringing with her years of expertise in clinical dermatology, which is still visible in her skincare clinics Dr. Mainz. Her son, current CEO Dr. William Hung, summarizes the Maria Von mentality, saying that “we believe skin is not just an outer-layer, it represents you, not only in terms of your expressions — it protects you — but also when you are unhealthy, you can see it.”

EXPERT ITEMS FROM MARIA VON

Partly motivated by her inability to help her sick father with pressure sores, and in the aftermath of a national disaster — the New Taipei City waterpark fire — Dr. Huang redefined the company with a change in direction.

Maria Von was the first company to import cultured epidermis technology — through the product JACE® — from Japanese company J-TEC, into Taiwan — the first stepping stone for Maria Von’s new regenerative medicine focus, which has shaped the R&D backbone that forms the spine of the company.

Maria Von’s expertise manifests itself in a range of inter-connected items, centering around regenerative healing. Their products display numerous applications of stem cells, including personalized biologics which provide stem cell culture regeneration, and mesenchymal stem cell banking (Taiwan’s leading adult cell bank). They top off this portfolio with their own biopharmaceutical consulting services.

Currently, Maria Von’s versatility is allowing them to assist a wide range of patients. Their regenerative PRP treatment contributes to the healing of burn victims, and the intrinsic

malleability of stem cells allows them to play a role in a vast array of treatments. Furthermore, their R&D focus continues to present new possibilities; for example the emerging market of artificial skin, which provides R&D labs with a solution to increasingly tight animal testing restrictions.

With their R&D-centered biotechnology services in full-swing, Maria Von has also established their own skincare product brands in Taiwan, China and Southeast Asia. Their multifaceted products meet skincare needs including treatment of acne, anti-aging, moisturizing and gentle clearing. In the coming years they have high ambitions as they look to take the next step of their journey and aim to become IPO listed in the future. ●

マインツ・美形クリニック
麥茵茲美形診所
Dr. Mainz Clinic



瑪旺幹細胞醫學生物科技股份有限公司
Maria Von Med-Biotechnology Co., LTD

CHAHENG PRECISION: CRUISING AT TIER ONE ALTITUDE

A 100% Taiwanese company, Chaheng Precision collaborates with the best of the best as Taiwan’s only tier one aerospace manufacturer.

Chaheng Precision was an entirely different company when Jane Chi, Chairman, took it over. Since her taking the reins, the company has become Taiwan’s only tier one aerospace manufacturer, collaborating with the likes of GE Aviation and Safran Group as they specialize in the creation of aeroengine fan blades. Chaheng Precision entered into the aerospace market with high ambitions, and the goal of manufacturing for tier one, refusing to go any lower. Within a short amount of time, their achievement had already matched their ambition, as Chi proudly states “they said it takes 40 years to do blades. We made it happen within 18 months.”

Having established themselves, the company continues to push forward, ensuring that it is a company of tomorrow rather than yesterday. The need for constant progress is summarized by Chi, who says “you need to continue innovating to go beyond and this is what we have been doing.” Such is the meticulous nature of their



work, “if you find any crack or scratch, it is scrapped then; they have to start all over again.” Furthermore, R&D requires more than “10,000 measurements”, to create engine blades, which “could cost one Mercedes-Benz, or BMW” each. Given the microscopic detail and the burden of the lives of passengers, impeccable R&D and the most advanced technology at hand is a necessity. To that end, firstly, Chaheng recently opened a new R&D center of around 19,800 square meters.

Secondly, they are using AI, Big Data, Internet of Things, industrial automation and smart machinery to increase efficiency and

accuracy. These 4IR technologies are also being integrated into the company’s innovation, as Chi informs us “this year we are going to bring our original products, including future products as well as current factories to an intelligent level.” This forward thinking also applies to the company’s values, and appreciation of sustainability’s importance.

Along with ambition and vision, the company also holds pride — pride in being from Taiwan. Whilst having had the opportunity to move the company, Chi lauds Taiwan’s human capital and does not see the advantage in leaving, considering that wherever their collaborators or clients are based, from the United States to China, Chaheng Precision work with the top 3 companies of any given location. ●


Chaheng Precision

LeadBest — Empowering the Digital Future

Nowadays, digitalization is not an option; it is simply a prerequisite for any company with ambitions of surviving and thriving in an increasingly competitive world. However, digitalization is not an easy, overnight process, especially in more traditional industries and this means that executive advisory companies such as Taiwan-based LeadBest Consulting Group are set to rise to prominence.

With a commitment to “digital empowerment,” LeadBest specializes in the use of digital innovation to help companies maximize their business advantages. Through an in-depth consultancy interview service which helps identify company core strengths, as well as working with customers, LeadBest helps develop the most commercially valuable digital empowerment strategy for clients. Moreover, with their 5 digital forces ABCDE (AI, Blockchain, Cybersecurity, Digital, Enterprise core value), clients are able to enhance their competitiveness, develop new business models and create new revenue streams. “Technology-driven business development is the core of LeadBest Consulting Group,” says Chia Hsien Lee, company CEO and Founder.

VENTURE STUDIO AS A SERVICE

With over 300 projects undertaken alongside companies such as Starbucks and Coca-Cola, LeadBest has gained experience in countries such as the USA, Hong Kong, Japan, Philippines, Myanmar and Singapore, across a wide range of industries including retail, IT, finance and catering. A fundamental part of future growth will be LeadBest’s Venture Studio, described as “our core model” by Mr. Lee, which comprises three distinct models: breeding and incubating, internal innovation, and product development which, unlike traditional VC firms, provide entrepreneurs with more integrated resources, technologies, expertise and time.

Looking ahead to the future, Mr. Lee appears bullish as he looks to Southeast Asia as a key market for further growth and, as the need for digitalization grows by the day, it seems he has every right to be confident about what lies on the horizon. “LeadBest Consulting Group is looking forward to becoming the first and most reliable venture studio in Asia,” he adds. ●



**LeadBest
Consulting
Group**

TAISHIN FINANCIAL HOLDINGS — YOUR SMART PARTNER



Winning customer recognition and society’s trust has always been the goal of Taishin Financial Holdings. As a leading Taiwanese financial institution, Taishin recognizes the foundation of success is to maintain consistent and steady growth alongside its customers through its core values of integrity, commitment, innovation and collaboration — principles which help forge lasting client relationships.

Taishin has invested heavily in cutting-edge banking technologies, utilizing AI and big data to provide advanced quality services. Its new ATMs allow customers to get access to cash services via biometric identification. Furthermore, Taishin is the first among its peers to roll out a digital banking service app, called “Richart”, with over 50% of digital banking market share in Taiwan. These innovations qualified Taishin for numerous prestigious awards, including Best Consumer Digital Bank in Taiwan (2020) from Global Finance, Best Digital Bank in Taiwan (2020) from Asiamoney, and Best Private Bank for Big Data Analytics and AI in Asia (2018-2020) from The Banker/PWM. Moreover, Taishin is committed to contributing to a sustainable future for all by adhering to the Equator Principles and the implementation of ESG-based policies, with a focus on low-carbon operations and sustainable finance. Such initiatives have seen Taishin rewarded with a place in the Dow Jones Sustainability Index for a second time. Furthermore, through numerous charity and welfare initiatives, Taishin aligns itself with the social impacts recommended in the UN’s Sustainable Development Goals. “Taishin proudly joins hands with the government, fellow financial institutions, and our clients to spur the development of responsible economic, environmental, and social sustainability frameworks,” says Welch Lin, President of Taishin Financial Holdings.

Looking ahead, the recruitment and extensive training of top-tier financial professionals, as well as the opening of new overseas branches in the Asia-Pacific region, will further support Taishin’s ambitions to become a regional player in financial services. “I am very confident in the development of Taishin Holdings,” says Mr. Lin. “In terms of size, we have a very healthy organic growth and we will be more aggressive in the Asia region.” ●



Taishin Holdings

TECO — Welcome to 4IR Smart Energy

TECO is Taiwan’s predominant energy conglomerate company developing and designing infrastructure supportive solutions and energy efficient electrical products.



Sophia Chiu,
Chairman of TECO

Traded on Taiwan’s Stock Exchange, TECO is recognized for its award winning corporate social responsibility and globally diversified business portfolio. Through the Company Vision (Energy Savings, Emissions Reduction, Intelligence and Automation), TECO products — such as the industry recognized Motors, Drives, E-Houses, Smart Factory Solutions, and Energy Storage Systems — can be found worldwide.

DEVELOPING SMART FACTORY SOLUTIONS

From the onset of the Industry 4.0 IoT revolution, TECO set up its AI team and invested in IoT Smart Manufacturing to provide factory productivity enhancements with automation and digital tools. TECO’s Chairman Sophia Chiu stated, “Smart production lines maintained our manufacturing resilience and kept the company’s competitiveness during the Sino-US trade war and COVID-19 epidemic.” TECO’s AI team also developed related agile engagement technologies and derivative solutions, such as the AGV solutions being introduced to industrial and commercial sites, through its Meal-Delivery service robots, AMR, and its disinfection service robot early this year.

RELEASING EV POWERTRAIN SYSTEM

For the EV Powertrain, TECO launched its modularized expandable PM synchronous motor and drive solution for cycles, passenger cars, light-duty commercial cars, and the electric bus. “This high-performance powertrain is engaging in several joint-development projects in the markets of Asia-Pacific, Southeast Asia, and even Europe”, said Chairman Chiu.

This demonstrates that TECO thinks ahead to provide its customers with energy solutions for a better and safer world. ●



CDIB Capital Group, an affiliate of China Development Financial — Reaching New Heights

CDIB Capital Group appoints new Chairman and adds top-level executives to spearhead its transformative next stage in global asset management.



Angelo J.Y. Koo, Chairman

CDIB Capital Group (CDIB), part of China Development Financial (CDF, TWSE: 2883), has played a leading and pioneering role in Taiwan's venture capital and has been a key contributor to Taiwan's robust economic progress throughout the later half of the 20th century.

NEW CHAPTER, EXPANDED CAPABILITIES

Today, CDIB is ushering in a new chapter – shifting its proprietary investment business into asset management; overseeing in excess of US\$2.5 billion of proprietary and third-party capital from investors globally. As a strategic emphasis on expanding the Group's capabilities, CDIB appointed a new Chairman and added senior executives to lead the group's next stage in global asset management.

In October 2019, the CDIB Board appointed Angelo J.Y. Koo as Chairman to spearhead

CDIB's development as a global asset manager. Mr. Koo was previously President and CEO of CDF and Chairman of CDIB's predecessor, China Development Industrial Bank.

New senior additions to CDIB include William Ho, who held appointments as Partner of CVC Capital Partners and Head of CVC's Greater China office. Alex Ying, veteran of the Carlyle Group, was appointed Head of the newly created Buyout Group. Tor Trivers also joined from Carlyle as Head of Structured Credit. Robert Liu, former Asia Head of Venture Investments at Johnson & Johnson, was appointed Co-Head of the Healthcare Group.

These appointments underscore CDIB's commitment to building a world-class investment team as it expands its platform in Asia and beyond.

GLOBAL EXPANSION, REGIONAL MID-MARKET BUYOUTS

Over recent years, CDIB has successfully widened its proprietary mandate by managing third-party capital from high-net-worth individuals, family offices, sovereign wealth funds, pension funds, funds of funds, insurance companies, and banking institutions worldwide.

Alongside broadening its expertise, CDIB has been sharpening its strategic focus, underpinned by mid-market buyout opportunities set in Taiwan, such as the take-private control deal of Jintex Corporation in June 2019. Going forward, CDIB is keen to leverage its deep market insights to continue unearthing attractive investment opportunities. ●



中華開發金控
CHINA DEVELOPMENT FINANCIAL

中華開發資本
CDIB CAPITAL GROUP

ZYLUX ACOUSTIC – STRONG TRADITIONS, EXCITING FUTURE

With 40 Years of Audio Expertise, Zylux Acoustic continues to grow from strength to strength as a market leader thanks to investment in key areas such as Dolby ATMOS and Smart Audio technology.

THE SOUND OF THE FUTURE

We are living in a transformative time wherein real-life experiences are seamlessly integrated with the digital sphere, with the emergence of smart devices and Internet of Things (IoT) systems. Today, even how we listen has shifted significantly amidst the current audio revolution that has given rise to Smart Audio.

Taiwan-based Zylux Acoustic continues to ride on the crest of this next wave of sound innovation, being one of the first audio Original Design Manufacturers (ODMs) to bring Dolby ATMOS and DTS immersive surround sound from theaters to home entertainment. The company's dynamic, future-oriented approach has positioned it as a leader in the Dolby ATMOS soundbar category.

AUDIO EVOLUTION

"The audio industry has changed drastically, and those who are unable to react to the changes will quickly be diminished," says Zylux Acoustic CEO Will Lu. Indeed, Zylux has seen a palpable change in the market from its early days; competitors have come and gone but thanks to a willingness to evolve while maintaining its commitment to quality, the company has stood



the test of time and is poised to grow even further in the coming years.

Founded in 1980, the company is globally recognized as a standard-bearer for OEM/ODM audio product innovation, quality and design, evidenced by several long-term partnerships with some of the world's most renowned audio brands and technology innovators, including Qualcomm, MTK, Cirrus Logic, and Skyworks. Zylux is a Google-certified GVA Partner and has collaborated with the tech giant in the area of Smart device OS platform development, specifically with Google Voice Assistant. Many of Zylux's latest TV soundbars and portable speakers are embedded with connected audio and Smart/ Voice capability, including Google Cast, GVA and Alexa.

"If Google chose us, it is proof of something, it means that we are qualified in terms of engineering, capability, and also shows recognition on the market," claims CEO Mr. Lu.

SOUND REVOLUTION

Well aware that today's global marketplace operates 24 hours per day, Zylux has a global presence, with operations in Taiwan, China, South Korea, Japan and the United States.

With world-class production plants in China and Vietnam, Zylux aims to meet the growing production demands of the highly competitive audio industry by combining new technologies, skillful engineering and uncompromised quality at a competitive price. Years of design experience in connected and smart audio and TV soundbars, combined with Zylux's engineering capability, gives Zylux a good foundation and a front row ticket to the implementation of advanced audio technologies in the future.

A strong past merged with a future-oriented approach places Zylux firmly at the forefront of the digital sound revolution. ●

ZYLUX

WIN — Leading Global Communication Through Innovative Compound Semiconductor Solutions

With over twenty years of organizational excellence, WIN Semiconductors continues to grow as the world's largest pure-play III-V compound semiconductor foundry.



Dennis Chen
Chairman of the
Board & President

The bedrock of Taiwan's export-led economy has traditionally been the semiconductor industry and, given the new wave of emerging technologies such as artificial intelligence (AI), 5G and Internet of Things (IoT) as well as the increasing demand for consumer electronics, Taiwan's most innovative companies in this sector are well positioned for future growth. More specifically, compound semiconductors are set to become a key area of rapid development and this is where market leaders like WIN Semiconductors Corp. have really come into their own.

Having recently celebrated its landmark twentieth anniversary in October 2019, WIN is now recognized as the world's largest pure-play III-V compound semiconductor foundry and has grown exponentially in the last twenty years to become the dominant player in the market, with over 70% worldwide foundry market share. Using state-of-the-art GaAs (gallium arsenide) technology, WIN supplies HBT and pHEMT MMIC fabrication services to worldwide integrated circuit (IC) corporations and has been able to establish itself as a leading wafer semiconductor manufacturer. With MMIC technology at its core, WIN also provides optoelectronic device fabrication services for optical communication and 3D sensing applications while striving for fast turnaround time, cost-effective turn-key solutions and total quality control for customers. Furthermore, the company's one-stop service – from foundry to assembly and final test – enables reduced product manufacturing cycle times and more efficient supply chain management.



INVESTING IN THE FUTURE

Chairman of the Board and President of WIN, Dennis Chen, is the first to acknowledge that the need for constant research and innovation, while embracing change, is paramount to augmenting its position as the global market leader in wafer semiconductors manufacturing. "I believe that R&D is the only way of keeping our leading position, nowadays things are changing rapidly and the field is becoming more and more competitive." Each year, the company invests about 6% of total revenue in R&D and the results speak for themselves: in 2019, WIN recorded revenues of over US\$691M and achieved a substantial estimated growth in 2020. Such numbers are particularly noteworthy, even more so when compared to the current industry average of 0.9%. In 2019 alone, they delivered over 5 billion chips – the equivalent height of 1000 Taipei 101 towers if stacked one on top of another.

On the other hand, according to Deloitte, the global semiconductor sector's total revenue is set to rise up to US\$543 billion by 2022. This robust growth is expected to continue well into the coming decade due to demand for existing product enhancements through the implementation of new emerging technologies. This is precisely where WIN has positioned itself ahead of the curve in recent years. Through extensive research, the company has been able to leverage its expertise in compound semiconductors to meet growing demand in areas such as 5G, 3D sensing and aerospace industries, while also manufacturing chips for advanced technologies in satellite and telecommunications.

GLOBAL TRUST

A commitment to consistent quality, underpinned by a corporate culture based on R&D and innovation, has led WIN to become a key semiconductor provider to major tech companies around the world, providing fast and cost-effective foundry services in a broad range of applications from 50MHz to 150GHz. The company has created initiatives to foster a culture of creativity from within, whereby engineers are invited to submit their projects which are subsequently shortlisted and recognized at its annual awards ceremony.

Mr. Chen is well aware of growing global competition and the need to be even more client-oriented. As such, a firm commitment to manufacturing excellence and quality assurance is at the core of everything WIN does. "We have to focus on knowing our customers and the key is to earn our customers' trust," he adds. Staying true to its "We Excel, We Care" mission, the company operates on four fundamental values: accountability, innovation, customer satisfaction and quality. Forever in the pursuit of perfection, the employment of "Plan-Do-Check-Act" cycles ensures consistent, optimal product quality, ensuring a superior, compound semiconductor device and integrated circuit manufacturing foundry service.

MADE IN TAIWAN

Proud of its roots, WIN carries out all of its manufacturing in Taiwan with three production sites around Taoyuan City, less than 50km from Taipei.

Mr. Chen is optimistic that the semiconductor industry can continue to be the springboard for the development of other sectors in Taiwan by leveraging its key strengths: packaging, designing, testing, and manufacturing. "We can use the semiconductor industry as a core, using this unique position in terms of our IC designs while utilizing other semiconductor industry strengths such as our packaging, in-house testing and the entire ecosystem to connect every industry with the semiconductors in Taiwan," he says.

Moreover, WIN is fully committed to being responsible for the environment in which it operates and has pledged efforts to follow the United Nations' 17 Sustainable Development Goals. It aims to prioritize high-efficiency and low-energy consumption models to replace its equipment in the future. In 2019, it implemented eleven energy conservation and carbon emissions reduction plans. The foundations are in place for a sustainable future. ●



Yi-Chiu Group — Make Way For Generation 2.5

Jonathan Chin is far from your average 23-year-old, as he prepares to take on the task of filling the enormous boots of his father, A.K.A Taiwan's mineral oil guru.

Following the privatization of the Taiwanese oil industry in the late 80s, Yi-Chiu Group emerged as the giants of the mineral oil world in Taiwan. Their Chairman and Founder Chia-Hung Chin has since become known as the mineral oil guru of Taiwan; the group having not just oil, but international trade and environmental protection under the large umbrella of its businesses. That said, in its sixty-year-plus history, now is not the time to rest on laurels. Chia-Hung himself acknowledges that “the amount of natural gas and oil used in the petrochemical industry will slowly decrease.” Looking for solutions to this decrease, Chia-Hung’s approach to challenges does not appear to have changed a great deal. He talks about solutions to the early challenges faced by Yi-Chiu, and how he would “brainstorm for solutions every day, knowing that only through innovation could I turn this difficulty to opportunity.” This idea of innovation as a way of turning difficulty into opportunity, can be seen reflected as Yi-Chiu tries to negotiate the decline of the petrochemical industry that they predict. Branching into sustainable business and renewable energy is gradually being outlined as Yi-Chiu Group’s future. Chia-Hung’s son, Jonathan Chin, the youngest of seven siblings, appears to be the one who is going to manage this future, and is already playing a part in the transition towards it, having steered his father in the direction of sustainability.

FOLLOWING IN THE FOOTSTEPS

The world is Jonathan’s oyster. Yet, driven by commitment to Yi-Chiu Group, love for his father and a desire to leave a mark on the business world, Jonathan chose not to continue his studies in the United States, opting to return to Taiwan to help Yi-Chiu acclimatize to the business world of tomorrow. Explaining his thinking behind the early termination of his studies in the U.S. and subsequent return to Taiwan, Jonathan says “this big legacy is created by my father. And

I love my father. I want to think about what he cares about the most. His legacy could be gone in the future, and I do not want to see that.” Taking on the business when his father is gone is what Jonathan sees as “the best way to give back to his father.” Therefore, while his elder siblings have opted for alternative paths, the family business has continued to be the future he sees for himself and an opportunity which he relishes. On a personal level, a notion of a calling to the business world is noticeable when Jonathan talks about his lifelong ambitions. He reminisces “I had my own goal when I was a boy that I wanted to be a businessman; I wanted to have a huge company like Apple or Google.”

Despite his self-assuredness, and willingness to dive in at the deep end, the huge levels of pressure — as he looks to make his own mark in the wake of his father’s giant footsteps — are unignorable. He admits “I feel a tremendous amount of pressure. Everyone is holding up a magnifying glass to everything that I do, and they want to see what I am capable of.” He has nonetheless, found a way to constructively convert this pressure, and he even goes as far as to say that rather than hinder him, the pressure helps him “to make the right decisions and drives me to work harder.”

SUSTAINABILITY IS THE FUTURE

Just as pressure and expectation are driving forces behind Jonathan, he himself is the driving force behind Yi-Chiu’s growing shift towards sustainability. He describes it as the “key business of human nature and human beings.” It is not only the elephant in the room that is

climate change and the planet’s well-being that motivates Jonathan however, as he also believes “sustainability is what will make money in the future” and wants to make sure Yi-Chiu is ahead of the game on that front. To this end, Jonathan is heading operations at Fabu Green Technology and Yi Chun Green Technology. The latter offers



Chia-Hung Chin, Chairman & Founder, Yi-Chiu Group.
Jonathan Chin, General Manager of Yi-Chun Group.

the innovative solution of recycling diapers, and pulling out core materials, notably fiber, for reuse. Fabu Green Technology on the other hand, uses the versatile light stone technology, created from recycled glass, to facilitate greening, agriculture, aquaculture, and even environment-friendly civil engineering. Yi-Chiu Group is also moving into renewable energy as one of the shareholders of Century Wind Power. Chia-Hung also highlights the opportunity of wind power in Taiwan. He explains that according to a report by 4C Offshore, “of the top 20 zones of potential around the world, 16 are in the Taiwan Strait.” He adds that “98% of energy sources in Taiwan are imported,” making wind power an even more imperative need to lower the “high in risk” dependency on this often unstable market.

Alongside these sustainable initiatives, aluminum tire company Cherubim Alloy and U-Well Biomedical, a biotech company in which Yi-Chiu has invested in, are also among the projects Jonathan is undertaking to further diversify Yi-Chiu’s portfolio.

A LIFETIME OF PREPARATION

In Jonathan Chin, Yi-Chiu has not only found someone willing to take on the challenge of succeeding its founder, but someone truly prepared to take the business forward, whilst not ignoring the value of its past. Bearing in mind both future and legacy, Jonathan does not shrink in the shadow of his father, but through osmosis, has made himself stronger. He explains “most of my experience and knowledge came from observing what my father was doing. I did not learn from books and no-one taught me. Years of observation of what my father was doing and thinking... has prepared me for who I am.” Jonathan has been preparing for the responsibility of taking the reins of Yi-Chiu Group his whole life, and if the early signs are anything to go by, he will be more than ready when the moment comes. ●

“Most of my experience and knowledge came from observing what my father was doing. I did not learn from books and no-one taught me. Years of observation of what my father was doing and thinking...has prepared me for who I am.”